Details for New Drug Application (NDA): 208910
✉ Email this page to a colleague
The generic ingredient in FIRVANQ KIT is vancomycin hydrochloride. There are twenty-two drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the vancomycin hydrochloride profile page.
Summary for 208910
Tradename: | FIRVANQ KIT |
Applicant: | Azurity |
Ingredient: | vancomycin hydrochloride |
Patents: | 7 |
Medical Subject Heading (MeSH) Categories for 208910
Suppliers and Packaging for NDA: 208910
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
FIRVANQ KIT | vancomycin hydrochloride | FOR SOLUTION;ORAL | 208910 | NDA AUTHORIZED GENERIC | Wilshire Pharmaceuticals, Inc. | 52536-104 | 52536-104-05 | 1 KIT in 1 CARTON (52536-104-05) * 3.75 g in 1 BOTTLE (52536-094-05) * 147 mL in 1 BOTTLE (52536-084-05) |
FIRVANQ KIT | vancomycin hydrochloride | FOR SOLUTION;ORAL | 208910 | NDA AUTHORIZED GENERIC | Wilshire Pharmaceuticals, Inc. | 52536-106 | 52536-106-05 | 1 KIT in 1 CARTON (52536-106-05) * 7.5 g in 1 BOTTLE (52536-096-05) * 145 mL in 1 BOTTLE (52536-086-05) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SOLUTION;ORAL | Strength | EQ 25MG BASE/ML | ||||
Approval Date: | Jan 26, 2018 | TE: | AB | RLD: | Yes | ||||
Patent: | 10,493,028 | Patent Expiration: | Mar 13, 2035 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | 10,688,046 | Patent Expiration: | Mar 13, 2035 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | 10,959,946 | Patent Expiration: | Mar 13, 2035 | Product Flag? | Y | Substance Flag? | Delist Request? |
Complete Access Available with Subscription